Mental illnesses

Mental illnesses represent a small group in comparison to other therapeutic areas. Up until this time, 8 medicinal products have been assessed in 11 resolutions on illnesses such as schizophrenia, depression or ADHD. Of the subpopulations, 0% have seen a major additional benefit, 9.1% a considerable, 11% a minor and 0% a non-quantifiable additional benefit. The G-BA could see no additional benefit for 79.9% of the subpopulations weighted according to their share of patients in the respective resolution, corresponding to 91% of the maximum number of 5.96 million patients treatable with these medicinal products.